NASDAQ:MNKD MannKind - MNKD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. $4.04 +0.09 (+2.28%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.94▼$4.0950-Day Range$3.95▼$5.6352-Week Range$2.61▼$5.73Volume2.43 million shsAverage Volume3.27 million shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MannKind MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside60.9% Upside$6.50 Price TargetShort InterestBearish13.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$52,700 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.14) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 starsMedical Sector833rd out of 986 stocksPharmaceutical Preparations Industry400th out of 477 stocks 3.5 Analyst's Opinion Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, MannKind has a forecasted upside of 60.9% from its current price of $4.04.Amount of Analyst CoverageMannKind has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.22% of the outstanding shares of MannKind have been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in MannKind has recently increased by 0.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNKD. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 19 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat Follows11 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,700.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.16% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MannKind are expected to grow in the coming year, from ($0.14) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About MannKind (NASDAQ:MNKD) StockMannKind Corp. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic products and devices for those with endocrine and orphan lung diseases. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.Read More Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Stock News HeadlinesMarch 15, 2023 | nasdaq.comMannKind Becomes Oversold (MNKD)March 14, 2023 | finance.yahoo.comBreakeven On The Horizon For MannKind Corporation (NASDAQ:MNKD)March 23, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 7, 2023 | finance.yahoo.comMannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare ConferenceFebruary 27, 2023 | benzinga.comMannKind To Rally Around 30%? Here Are 10 Other Analyst Forecasts For MondayFebruary 24, 2023 | fool.comMannKind (MNKD) Q4 2022 Earnings Call TranscriptFebruary 23, 2023 | finance.yahoo.comMannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial ResultsFebruary 22, 2023 | finance.yahoo.comMannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD ConferenceMarch 23, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 16, 2023 | finance.yahoo.comMannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023February 15, 2023 | finance.yahoo.comAs MannKind Corporation (NASDAQ:MNKD) gains 6.3%, insiders who bought last year may be wishing they had bet higherFebruary 10, 2023 | finance.yahoo.comMannkind Corporation to Participate in the SVB Securities Global Biopharma ConferenceFebruary 9, 2023 | finance.yahoo.comHere's What Could Help MannKind (MNKD) Maintain Its Recent Price StrengthJanuary 24, 2023 | finance.yahoo.comMannKind Corporation to Participate in the Lytham Partners Investor Select ConferenceJanuary 23, 2023 | finance.yahoo.comMannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung DiseaseJanuary 17, 2023 | finance.yahoo.comMannKind's (NASDAQ:MNKD) investors will be pleased with their impressive 183% return over the last three yearsJanuary 5, 2023 | finance.yahoo.comMannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare ConferenceDecember 31, 2022 | finance.yahoo.comIs There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 44% Undervaluation?December 6, 2022 | finance.yahoo.comAfter Golden Cross, MannKind (MNKD)'s Technical Outlook is BrightNovember 30, 2022 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) is a favorite amongst institutional investors who own 52%November 22, 2022 | seekingalpha.comMannKind Is Poised To Turn A Profit And Shares Could Get CheaperNovember 10, 2022 | finance.yahoo.comMannKind Third Quarter 2022 Earnings: Beats ExpectationsNovember 10, 2022 | finance.yahoo.comMannKind to Present Two Posters at 22nd Annual Diabetes Technology MeetingNovember 8, 2022 | finance.yahoo.comMannKind Corporation (MNKD) Q3 2022 Earnings Call TranscriptNovember 7, 2022 | seekingalpha.comMannKind Q3 2022 Earnings PreviewNovember 6, 2022 | reuters.comMNKD.O - MannKind Corp | Stock Price & Latest News | ReutersNovember 1, 2022 | finance.yahoo.comMannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Company Calendar Last Earnings2/23/2023Today3/23/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MNKD CUSIP56400P20 CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees348Year Founded1991Price Target and Rating Average Stock Price Forecast$6.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+61.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,400,000.00 Net Margins-87.60% Pretax Margin-87.60% Return on EquityN/A Return on Assets-29.55% Debt Debt-to-Equity RatioN/A Current Ratio3.49 Quick Ratio3.17 Sales & Book Value Annual Sales$99.77 million Price / Sales10.63 Cash FlowN/A Price / Cash FlowN/A Book Value($0.95) per share Price / Book-4.23Miscellaneous Outstanding Shares263,924,000Free Float257,854,000Market Cap$1.06 billion OptionableOptionable Beta1.68 Social Links Key ExecutivesMichael E. CastagnaChief Executive Officer & DirectorSteven B. BinderChief Financial OfficerJoseph KocinskyChief Technology OfficerKevin KaisermanVice President-Medical Affairs & SafetyThomas HofmannChief Scientific OfficerKey CompetitorsOPKO HealthNASDAQ:OPKGeronNASDAQ:GERNLigand PharmaceuticalsNASDAQ:LGNDDynavax TechnologiesNASDAQ:DVAXImmunoGenNASDAQ:IMGNView All CompetitorsInsiders & InstitutionsMichael CastagnaSold 10,000 sharesTotal: $52,700.00 ($5.27/share)Voya Investment Management LLCSold 643,942 shares on 2/28/2023Ownership: 0.296%Alliancebernstein L.P.Bought 5,100 shares on 2/16/2023Ownership: 0.097%State of Wisconsin Investment BoardBought 2,250 shares on 2/15/2023Ownership: 0.093%Legal & General Group PlcBought 3,720 shares on 2/15/2023Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions MNKD Stock - Frequently Asked Questions Should I buy or sell MannKind stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares. View MNKD analyst ratings or view top-rated stocks. What is MannKind's stock price forecast for 2023? 1 analysts have issued 1 year price objectives for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $7.00. On average, they predict the company's share price to reach $6.50 in the next year. This suggests a possible upside of 61.7% from the stock's current price. View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts. How have MNKD shares performed in 2023? MannKind's stock was trading at $5.27 at the start of the year. Since then, MNKD stock has decreased by 23.7% and is now trading at $4.02. View the best growth stocks for 2023 here. When is MannKind's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our MNKD earnings forecast. How were MannKind's earnings last quarter? MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Thursday, February, 23rd. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The biopharmaceutical company had revenue of $36.06 million for the quarter, compared to analysts' expectations of $35.51 million. The firm's quarterly revenue was up 188.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.11) EPS. What ETFs hold MannKind's stock? ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Global X Aging Population ETF (AGNG), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC) and Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD). What is MannKind's stock symbol? MannKind trades on the NASDAQ under the ticker symbol "MNKD." Who are MannKind's major shareholders? MannKind's stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.37%), Geode Capital Management LLC (1.87%), Emerald Advisers LLC (1.41%), Schonfeld Strategic Advisors LLC (1.09%), Renaissance Technologies LLC (0.74%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MannKind's stock price today? One share of MNKD stock can currently be purchased for approximately $4.02. How much money does MannKind make? MannKind (NASDAQ:MNKD) has a market capitalization of $1.06 billion and generates $99.77 million in revenue each year. The biopharmaceutical company earns $-87,400,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. How many employees does MannKind have? The company employs 348 workers across the globe. How can I contact MannKind? MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081. This page (NASDAQ:MNKD) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.